VolitionRx is a publicly
traded life sciences company that develops innovative solutions for blood-based
diagnostics of different types of cancers. The company is focusing particularly
on the development of detection measures for early-stage cancers, of which it
believes that current diagnostics measures are inadequate.
At the basis of VolitionRx’s
development efforts is Nucleosomics®, the company’s proprietary, non-invasive
technology that measures and determines nucleosome structures within human
blood. When cancer cells die, they release nucleosomes into the blood,
providing a medical opportunity for actual cancer detection. Dr. Jay Micallef,
VolitionRx’s Chief Scientific Officer, says that there are many cancer
diagnostics tests available that only detect a patient’s risk of cancer. By being
able to detect and determine the number of nucleosomes present within a
patient’s blood, however, Nucleosomics builds on top of these current measures’
capabilities: it detects whether cancer is actually present.
Currently, VolitionRx is
focusing its primary development efforts on colorectal cancer, a deadly cancer
that is one of the deadliest in the United States. According to the Center for
Disease Control and Prevention, in 2010 over 130,000 people were diagnosed with
colorectal cancer in the United States. The American Cancer Society reports
that chances for incidence of colorectal cancer increase as a person ages: some
9 out of 10 patients who are diagnosed with colorectal cancer are over 50 years
of age.
This age trend is medically
relevant considering the longer lifecycles of today’s aging populations.
Historically unprecedented amounts of Americans are moving into the elderly
stage of life and requiring greater amounts of medical attention. To
illustrate: beginning in 2011, each day an additional 10,000 Americans have
reached 65 years of age, a daily trend that will likely persist until around
2030. With these increased requirements for sophisticated and available medical
care, the healthcare sector has become more needing of medical technologies
that are inexpensive, accurate, and scalable—especially in regard to cancer
diagnostics.
VolitionRx helps fill this
medical gap by providing diagnosis methods that are more likely to detect
cancer in its early stages, instead of the later stages of affliction when
patient survival rates drop. In short, by making early-stage cancer detectable,
VolitionRx’s diagnostic tests will substantially increase a patient’s chances
for cancer survival.
Backed by the efforts of a
business-savvy corporate and scientific management, VolitionRx may be on the
cusp of changing mainstream methods for cancer diagnosis in the United
States—and the world.
For more information, visit:
www.volitionrx.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
